William Blair Weighs in on Catalent, Inc.’s Q2 2018 Earnings (CTLT)
Catalent, Inc. (NASDAQ:CTLT) – Research analysts at William Blair cut their Q2 2018 EPS estimates for Catalent in a research note issued on Tuesday. William Blair analyst J. Kreger now anticipates that the company will post earnings of $0.30 per share for the quarter, down from their previous forecast of $0.35. William Blair has a “Ourperform” rating on the stock. William Blair also issued estimates for Catalent’s Q4 2018 earnings at $0.57 EPS, Q1 2019 earnings at $0.24 EPS, Q2 2019 earnings at $0.36 EPS and Q3 2019 earnings at $0.41 EPS.
Other research analysts also recently issued reports about the stock. Needham & Company LLC began coverage on shares of Catalent in a report on Tuesday, September 12th. They issued a “hold” rating and a $42.00 price target for the company. BidaskClub downgraded shares of Catalent from a “buy” rating to a “hold” rating in a report on Friday, September 15th. Piper Jaffray Companies reissued a “buy” rating and issued a $45.00 price target on shares of Catalent in a report on Tuesday, August 29th. Bank of America Corporation reissued a “buy” rating and issued a $40.00 price target (up from $38.00) on shares of Catalent in a report on Tuesday, August 29th. Finally, Zacks Investment Research downgraded shares of Catalent from a “buy” rating to a “hold” rating in a report on Friday, August 18th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $42.11.
Shares of Catalent (NASDAQ:CTLT) traded down $0.12 during trading hours on Thursday, reaching $38.00. 1,035,942 shares of the company’s stock traded hands, compared to its average volume of 919,394. Catalent has a 1 year low of $22.94 and a 1 year high of $43.39.
Catalent (NASDAQ:CTLT) last announced its quarterly earnings results on Monday, November 6th. The company reported $0.21 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.01. Catalent had a net margin of 10.02% and a return on equity of 36.29%. The firm had revenue of $543.90 million during the quarter, compared to the consensus estimate of $490.75 million. During the same period last year, the firm earned $0.16 EPS. The business’s quarterly revenue was up 23.0% compared to the same quarter last year.
Several institutional investors have recently bought and sold shares of CTLT. OppenheimerFunds Inc. raised its position in shares of Catalent by 29.2% during the 1st quarter. OppenheimerFunds Inc. now owns 18,737 shares of the company’s stock valued at $530,000 after buying an additional 4,237 shares in the last quarter. Teachers Advisors LLC raised its position in Catalent by 5.0% in the 1st quarter. Teachers Advisors LLC now owns 173,062 shares of the company’s stock worth $4,901,000 after purchasing an additional 8,314 shares during the period. PNC Financial Services Group Inc. raised its position in Catalent by 66.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 6,070 shares of the company’s stock worth $173,000 after purchasing an additional 2,425 shares during the period. Legal & General Group Plc raised its position in Catalent by 46.4% in the 1st quarter. Legal & General Group Plc now owns 82,380 shares of the company’s stock worth $2,335,000 after purchasing an additional 26,098 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in Catalent by 10.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,403,258 shares of the company’s stock worth $39,741,000 after purchasing an additional 137,335 shares during the period.
In other news, SVP Christine Dolan sold 1,594 shares of the firm’s stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $38.75, for a total transaction of $61,767.50. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.